New virus-like particles increase prime editing efficiency up to 170-fold

Efficient delivery of prime editing components is challenging due to their large size of around 6,4 kb, which does not fit into AAVs. But now, the inventor of prime editing, David Liu, has addressed the problem by developing so-called prime editor engineered virus-like particles (PE-eVLPs). 

By: Gorm Palmgren - Jan. 11, 2024
News

#CRISPRMED24

The all-in-one virus-like particles were developed through extensive engineering of each major component. They can contain all the needed components - prime editor proteins, prime editing guide RNAs, and nicking single guide RNAs. eVLP architectures that facilitate cargo release and cargo localisation were also optimised.

The newly engineered v3 and v3b PE-eVLPs function as transient ribonucleoprotein complexes and exhibit a staggering 65- to 170-fold increase in editing efficiency in human cells compared to previous base editor constructs.

In two genetic blindness mouse models, a single injection of v3 PE-eVLPs resulted in significant prime editing, protein expression restoration, and partial visual function recovery. The optimised PE-eVLPs offer enhanced safety by minimising off-target editing and eliminating the risk of oncogenic transgene integration during the in vivo delivery of prime editor ribonucleoproteins.

The research was published on Monday in Nature Biotechnology by David Liu and colleagues at the Broad Institute of MIT and Harvard. You can read the paper here.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagMissing linksHashtagNewsHashtagCRISPR Therapeutics AG

News: New virus-like particles increase prime editing efficiency up to 170-fold
CLINICAL TRIALS
Refractory Hypercholesterolemia, NCT06451770
Sponsors:
Verve Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Huntington's Disease, (NCT05032196)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine